Autoimmune neuromuscular junction disorders are rare. However, myasthenia gravis is
being increasingly recognised in people older than 50 years. In the past 5–10 years …

Background Myasthenia gravis (MG) leads to exertion-dependent muscle weakness, but
also psychological and social well-being are limited. We aim to describe the burden of …

This study aimed to review studies focused on the affective comorbidities associated with
myasthenia gravis and to determine the extent to which neuromuscular treatment modalities …

There are substantial disease and health-related quality-of-life (HRQoL) burdens for many
patients with myasthenia gravis (MG), especially for those whose disease symptoms are not …

Background Myasthenia gravis (MG) is a rare, chronic, debilitating, unpredictable, and
potentially life-threatening neuromuscular disease. There is a lack of real-world data on …

Abstract Introduction/Aims Limited knowledge exists on treatment patterns in clinical practice
in patients with myasthenia gravis (MG). In this study we examined MG treatment patterns in …

Introduction Myasthenia gravis is characterized by fluctuating muscle weakness that
improves with rest and worsens with effort or throughout the day. Areas Covered …

Introduction Even treated, myasthenia gravis (MG) continues to represent a significant
burden and might continuously affect patients' quality of life (QoL). The aim of our …

Background Depressive symptoms in myasthenia gravis (MG) are common, may mimic other
disease features, and contribute to misdiagnosis and diagnostic delay. Nevertheless, the …

Introduction Myasthenia gravis (MG) is a rare, debilitating, chronic disorder caused by the
production of pathogenic immunoglobulin G autoantibodies against the neuromuscular …